MB-6 + fluorouracil + leucovorin + oxaliplatin

MB-6 + fluorouracil + leucovorin + oxaliplatin is a combination regimen consisting of the investigational agent MB-6 together with three established chemotherapy drugs—fluorouracil, leucovorin (also known as folinic acid), and oxaliplatin. Fluorouracil is an antimetabolite that inhibits thymidylate synthase, disrupting DNA synthesis in rapidly dividing cells. Leucovorin enhances the binding of fluorouracil to its target enzyme, increasing its cytotoxicity. Oxaliplatin is a platinum-based chemotherapeutic that forms DNA crosslinks and induces apoptosis in cancer cells. The combination of these three agents (commonly known as FOLFOX) is widely used for colorectal and other gastrointestinal cancers[6][4]. The mechanism and role of MB-6 are not specified in available literature; it may be an experimental or code-named compound under investigation for synergistic effects with standard chemotherapy.

Other names

FOLFOX (for the fluorouracil + leucovorin + oxaliplatin component)